Outcomes and quality of care in acute myeloid leukemia over 40 years

Cancer

Volumn 115, Issue 13, 2009, Pages 2903-2911

  Alibhai, Shabbir M H ^a,b,c,d   Leach, Marc ^a   Minden, Mark D ^c,e   Brandwein, Joseph ^c,e  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b TORONTO REHABILITATION INSTITUTE   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Acute myeloid leukemia; Age; Ontario Cancer Registry; Survival outcomes; Treatment patterns

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER CENTER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; COMORBIDITY; FEMALE; HEALTH CARE QUALITY; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT REFERRAL; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL TIME;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); QUALITY OF HEALTH CARE; REFERRAL AND CONSULTATION; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 67649617160     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24373     Document Type: Article

References (36)

1. Lowenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med. 1999;341:1051-1062. (Pubitemid 29451802)
2. Cartwright RA, Staines A. Acute leukaemias. Baillieres Clin Haematol. 1992;5:1-26.
3. Estey E, Dohner H. Acute myeloid leukaemia. Lancet. 2006;368:1894-1907. (Pubitemid 44794525)
4. Xie Y, Davies SM, Xiang Y, Robison LL, Ross JA. Trends in leukemia incidence and survival in the United States (1973-1998). Cancer. 2003;97:2229-2235.
5. Luke C, Nguyen AM, To B, et al. Myeloid leukaemia treatment and survival - the South Australian experience, 1977 to 2002. Asian Pac J Cancer Prev. 2006;7:227-233.
6. Pinto A, Zagonel V, Ferrara F. Acute myeloid leukemia in the elderly: biology and therapeutic strategies. Crit Rev Oncol Hematol. 2001;39:275-287. (Pubitemid 32750296)
7. Lowenberg B. Treatment of the elderly patient with acute myeloid leukaemia. Baillieres Clin Haematol. 1996;9:147-159. (Pubitemid 26114592)
8. Rowe JM, Andersen JW, Mazza JJ, et al. A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (>55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490). Blood. 1995;86:457-462.
9. Stone RM, Berg DT, George SL, et al. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B. N Engl J Med. 1995;332:1671-1677.
10. Hiddemann W, Kern W, Schoch C, et al. Management of acute myeloid leukemia in elderly patients. J Clin Oncol. 1999;17:3569-3576. (Pubitemid 29517929)
11. Gupta V, Minden MD, Schuh A, Wells R, Brandwein J. An evaluation of modified high-dose cytarabine (mHi-DAC)-containing postremission therapy in patients over age 60 years with acute myeloid leukemia: data from the Toronto Leukemia Study Group. Br J Haematol. 2002; 117(suppl 1):20-21.
12. Appelbaum FR, Gundacker H, Head DR, et al. Age and acute myeloid leukemia. Blood. 2006;107:3481-3485.
13. Craddock C, Tauro S, Moss P, Grimwade D. Biology and management of relapsed acute myeloid leukaemia. Br J Haematol. 2005;129:18-34. (Pubitemid 40524048)
14. Rao A, Cohen HJ. Symptom management in the elderly cancer patient: fatigue, pain, and depression. J Natl Cancer Inst Monogr. 2004;(32):150-157.
15. Baron F, Storb R. Hematopoietic cell transplantation after reduced-intensity conditioning for older adults with acute myeloid leukemia in complete remission. Curr Opin Hematol. 2007;14:145-151. (Pubitemid 46175099)
16. Leith CP, Kopecky KJ, Chen IM, et al. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. Blood. 1999;94:1086-1099.
17. Juliusson G, Billstrom R, Gruber A, et al. Attitude toward remission induction for elderly patients with acute myeloid leukemia influences survival. Leukemia. 2006;20:42-47.
18. Menzin J, Lang K, Earle CC, Kerney D, Mallick R. The outcomes and costs of acute myeloid leukemia among the elderly. Arch Intern Med. 2002;162:1597-1603. (Pubitemid 34773427)
19. Gupta V, Chun K, Yi QL, et al. Disease biology rather than age is the most important determinant of survival of patients ≥60 years with acute myeloid leukemia treated with uniform intensive therapy. Cancer. 2005;103:2082-2090. (Pubitemid 40605116)
20. Jehn U, Suciu S, Thomas X, et al. Non-infusional vs intravenous consolidation chemotherapy in elderly patients with acute myeloid leukemia: final results of the EORTCGIMEMA AML-13 randomized phase III trial. Leukemia. 2006;20:1723-1730. (Pubitemid 44590960)
21. Knipp S, Hildebrand B, Kundgen A, et al. Intensive chemotherapy is not recommended for patients aged >60 years who have myelodysplastic syndromes or acute myeloid leukemia with high-risk karyotypes. Cancer. 2007;110:345-352. (Pubitemid 47121895)
22. Mengis C, Aebi S, Tobler A, Dahler W, Fey MF. Assessment of differences in patient populations selected for excluded from participation in clinical phase III acute myelogenous leukemia trials. J Clin Oncol. 2003;21:3933-3939. (Pubitemid 46606206)
23. Holowaty EJ, Marrett LD, Fehringer G. Cancer Incidence in Ontario: Trends and Regional Variations. Toronto, Ontario, Canada: The Ontario Cancer Treatment and Research Foundation; 1995.
24. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis. 1987;40:373-383. (Pubitemid 17055592)
25. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613-619.
26. Hosmer DW, Taber S, Lemeshow S. The importance of assessing the fit of logistic regression models: a case study. Am J Public Health. 1991;81:1630-1635.
27. Lang K, Earle CC, Foster T, Dixon D, Van Gool R, Menzin J. Trends in the treatment of acute myeloid leukaemia in the elderly. Drugs Aging. 2005;22:943-955. (Pubitemid 41746575)
28. Piccirillo JF, Tierney RM, Costas I, Grove L, Spitznagel EL Jr. Prognostic importance of comorbidity in a hospitalbased cancer registry. JAMA. 2004;291:2441-2447. (Pubitemid 38669187)
29. Alibhai SM, Leach M, Tomlinson GA, Krahn MD, Fleshner NE, Naglie G. Is there an optimal comorbidity index for prostate cancer? Cancer. 2008;112:1043-1050.
30. Giles FJ, Borthakur G, Ravandi F, et al. The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia. Br J Haematol. 2007;136:624-627. (Pubitemid 46148199)
31. Milligan DW, Grimwade D, Cullis JO, et al. Guidelines on the management of acute myeloid leukaemia in adults. Br J Haematol. 2006;135:450-474. (Pubitemid 44596187)
32. Gupta V, Xu W, Keng C, et al. The outcome of intensive induction therapy in patients ≥70 years with acute myeloid leukemia. Leukemia. 2007;21:1321-1324. (Pubitemid 46831828)
33. Frohling S, Schlenk RF, Kayser S, et al. Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B. Blood. 2006; 108:3280-3288. (Pubitemid 44776864)
34. Birkmeyer JD, Finlayson EV, Birkmeyer CM. Volume standards for high-risk surgical procedures: potential benefits of the Leapfrog initiative. Surgery. 2001;130:415-422.
35. Birkmeyer JD, Sun Y, Goldfaden A, Birkmeyer NJ, Stukel TA. Volume and process of care in high-risk cancer surgery. Cancer. 2006;106:2476-2481.
36. Birkmeyer JD, Sun Y, Wong SL, Stukel TA. Hospital volume and late survival after cancer surgery. Ann Surg. 2007;245:777-783. (Pubitemid 46684108)